Key Immune Cells Linked to Better Kidney Cancer Outcomes
PD-1 treatment may help by shifting certain immune cells to fight diseases like kidney cancer; higher CD163-positive TAMs are linked to better outcomes.
Read More
Welireg Plus Cabometyx Shows Tumor Control in Kidney Cancer Trial
Adding casdatifan to Cabometyx therapy showed encouraging activity and was generally well tolerated in previously treated clear cell renal cell carcinoma.
In Vivo CAR T-Cell Approach May Lower Kidney Cancer Treatment Cost
Enabling patients to generate CAR T-cells internally could cut kidney cancer therapy costs, explained Dr. Wayne Marasco of Dana-Farber Cancer Institute.
Watch
Clinical Trial Confirms Keytruda and Lenvima Benefit in Kidney Cancer
Data from the KEYNOTE-B61 trial show tumor shrinkage in different types of kidney cancer, including papillary and chromophobe subtypes.
Metastasis-Directed Radiotherapy Shows Improved Kidney Cancer Outcomes
Stereotactic body radiotherapy costs less and has shown better safety compared with immunotherapy and tyrosine kinase inhibitors in patients kidney cancer.
Kidney Cancer Research Embraces Biology-Driven Precision Approach
Dr. Ari Hakimi highlighted how tumor profiling and molecular markers are expanding access to precision-based trials for kidney cancer.
Welireg Improves Quality-Adjusted Survival Time in Advanced RCC
Welireg improved quality-adjusted survival time versus Afinitor in advanced renal cell carcinoma, extending progression-free survival and reducing side effects.
Dual-Targeting CAR T Therapy Shows Potential in Advanced Kidney Cancer
Researchers are building on the success of CAR T therapy in blood cancers to explore its use in clear cell renal cell carcinoma, a type of kidney cancer.
Personalized Neoantigen Vaccines Show Lasting Tumor Control in Kidney Cancer
Early data suggest personalized neoantigen vaccines activate the immune system and sustain tumor control in some patients with kidney cancer.
How Personalized Cancer Vaccines Are Advancing Kidney Cancer Care
Personalized cancer vaccines may potentially represent a step forward in guiding the immune system to more precisely target kidney cancer.
Ojjaara May Improve Anemia and Reduce Transfusions in Myelofibrosis
An expert highlights the impact of anemia in myelofibrosis and presented Ojjaara as a possible treatment to reduce transfusions and improve outcomes.
What Should Patients with Multiple Myeloma Know After ASCO 2025?
Dr. Joshua Sabari and Dr. Nausheen Ahmed sat down to discuss topline takeaways in the realm of hematologic malignancies following the 2025 ASCO Meeting.
Experts Impart Notable Information and Updates for Those With Blood Cancers
The 2025 ASCO Annual Meeting brought many different updates to light in the realm of hematological malignancies, including multiple myeloma and lymphoma.
Advancements Reshape Treatment for Non-Small Cell Lung Cancer
Dr. Prantesh Jain and Dr. Joshua Sabari delved into the numerous advances in NSCLC following 2025 ASCO, highlighting the REZILIENT-1 and NeoADAURA trials.
Breaking Down the Impact of SERENA-6 for Some With Breast Cancer
Dr. Joshua K. Sabari and Dr. Julia E. McGuinness discussed the SERENA-6 trial and its outcomes for patients with ESR1-mutated HR+/HER2— breast cancer.
Why is Clinical Trial Enrollment Important for Those With Kidney Cancer?
Dr. Michael Serzan explains the importance of clinical trial enrollment for patients with kidney cancer and highlighted findings from the STELLA-002 trial.
The Person Behind Their Diagnosis: Understanding the Patient
Dr. Joshua Sabari and Jackie Herigodt discuss the Imerman Angels organization and the importance of recognizing the person behind their cancer diagnosis.
ctDNA-Guided Therapy May Improve Breast Cancer Outcomes
For patients with metastatic HR+/HER2— breast cancer, there were various trials to have come out of ASCO 2025 that are worth keeping your eye on.
New Treatment Options Emerging Across Lung Cancer Subtypes
Both non-small lung cancer and small cell lung cancer is a disease that now has various therapeutic options available, according to experts.
Understanding the Whole Person Behind their Cancer Diagnosis
Dr. Joshua K. Sabari and Jackie Herigodt sat down to discuss the importance of knowing a patient beyond their cancer diagnosis.
Rybrevant Combo Improves Lung Cancer Outcomes After Tagrisso Failure
Rybrevant plus chemotherapy improved response and delayed disease progression for patients with EGFR-mutated non–small cell lung cancer after Tagrisso.
Explaining Brain Cancer and Metastases Updates for Patients
The 2025 ASCO Annual Meeting highlighted key advances in brain cancer and brain metastases for patients affected by the disease.
Delving Into Brain Cancer Treatment Takeaways Following ASCO 2025
The de-escalation of therapy helps avoid unnecessary toxicity from treatment in patients with brain cancer, explained Drs. Joshua K. Sabari and Manmeet Singh Ahluwalia.
Where Compassion Meets Care in Breast Cancer
Sara Gideon, nurse practitioner, is a compassionate oncology nurse who supports patients with cancer, streamlines care and leads with dedication.
Breaking Down the VERIFY Trial for Patients With Polycythemia Vera
Dr. Aaron Gerds breaks down the outcomes of the phase 3 VERIFY trial, investigating rusfertide, for patients with polycythemia vera, a type of blood cancer.
Updates in Shared Decision-Making in Lung Cancer Following ASCO 2025
Treating patients with lung cancer always calls for a focus on informed and shared decision-making, according to expert oncologists.
What Should Patients With Lung Cancer Know After ASCO 2025?
Dr. Joshua K. Sabari and Dr. Prantesh Jain delve into key lung cancer outcomes from the 2025 ASCO Meeting that patients should be aware of.
Bringing Light to More Personalized Medicine in Lung Cancer After ASCO 2025
Expert oncologists Dr. Joshua K. Sabari and Dr. Eric K. Singhi break down key updates and takeaways in lung cancer treatment following ASCO 2025.
What Patients With Genitourinary Cancers Need to Know After ASCO 2025
Dr. Joshua K. Sabari and Dr. Daniel V. Araujo provide expert insights into genitourinary cancer updates from ASCO 2025.
What Patients With Genitourinary Cancers Should Know After ASCO 2025
Dr. Joshua K. Sabari sat down with Dr. Daniel V. Araujo to discuss topline takeaways from the 2025 ASCO Meeting across the realm of genitourinary oncology
